Heparin is given parenterally and
unfractionated heparin (UFH) has a half-life of about one to two hours after
infusion. The half-life of low-molecular-weight heparin (LMWH) is about four to
eight hours. Heparin is obtained naturally from mucosal tissues of slaughtered
meat animals such as porcine intestines or bovine lungs or prepared
synthetically.
Statistics:
Europe
Heparin Market is estimated to account for US$ 4,085.8 Mn in terms of value
by the end of 2027.
Europe Heparin Market: Drivers
Increasing prevalence of venous
thromboembolism (VTE) is expected to propel growth of Europe heparin market
over the forecast period. For instance, according to NHS Scotland’s 2018
report, 75,846 people were admitted to hospital for VTE in Scotland from 2008
to 2017.
Europe Heparin Market: Opportunities
Potential of LMWH in reducing
lung injury is expected to offer lucrative growth opportunities for players in
Europe heparin market. For instance, in April 2020, researchers from Chang Gung
Memorial Hospital, Taiwan, reported that LMWH reduced ventilation-induced lung
injury through hypoxia inducible factor-1α in a murine endotoxemia model.
Europe Heparin Market: Restraints
Risk of heparin induced
thrombocytopenia is expected to hinder growth of the market. Heparin-induced
thrombocytopenia (HIT) is a complication of heparin therapy. There are two
types of HIT: type 1 and type 2. Type 1 HIT occurs within two days of heparin
therapy, while type 2 is observed within 4 days to 10 days of heparin therapy.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3960
Key Takeaways:
Europe heparin market was valued
at US$ 2,698.7 Mn in 2019 and is forecast to reach a value of US$ 4,085.8 Mn by
2027 at a CAGR of 6.1% between 2020 and 2027. Increasing prevalence of venous
thromboembolism (VTE) is expected to propel growth of Europe heparin market
over the forecast period
Low Molecular Weight Heparin
segment held dominant position in Europe heparin market in 2019, accounting for
81.4% share in terms of value, followed by Ultra Low Molecular Weight Heparin.
Increasing demand for Low Molecular Weight Heparin in reducing lung injury is
expected to drive the market growth.
Market Trends
Increasing prevalence of chronic
kidney disease is boosting growth of the market. For instance, according to the
study, ‘Prevalence and deaths for chronic kidney disease in 2017, and
percentage change of age-standardized rates by location, 1990–2017’ published
in February 2020, U.K. recorded around 5,636,676 cases of chronic kidney
disease in 2017.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/europe-heparin-market-3960
Major players in the market are
sourcing active pharmaceutical ingredients from Europe. For instance, in
November 2019, Fresenius Kabi launched preservative-free Heparin Sodium
Injection, USP in 5,000 USP units per 0.5 mL in Simplist ready-to-administer
prefilled syringes, in the U.S. The drug’s active pharmaceutical ingredient is
sourced from Europe.
Europe Heparin Market:
Competitive Landscape
Major players operating in Europe
heparin market include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun
Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm
Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd.,
Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A.,
Syntex S.A., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd,
Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings,
Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
Europe Heparin Market: Key
Developments
Major players in the market are
focused on adopting collaboration strategies to expand their product portfolio.
For instance, in September 2019, Nichi-Iko Pharmaceutical, the parent company
of Sagent Pharmaceuticals, Inc., collaborated with Eisai Co., Ltd. for the
generic pharmaceutical business in China.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3960
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment